Shares of Krsnaa Diagnostics surged 4 percent on September 26, following the company’s announcement to acquire a 23.53 percent stake in Apulki Healthcare, a start-up focused on oncology and cardiology services. This acquisition will grant Krsnaa exclusive rights to provide diagnostic services in partnership with Apulki Healthcare.
Apulki Healthcare, founded in 2022, operates under a public-private partnership model, establishing and managing hospitals. The acquisition is expected to be finalized within the next three months.
At 9:54 am, Krsnaa Diagnostics shares traded at Rs 854.40 on the NSE in good investor sentiment.
Having pioneered a different business model within public-private partnerships, it goes without saying that Krsnaa Diagnostics is bound to benefit from the thrust of the government on expanding healthcare access into Tier II and Tier III cities. The firm has opened several CT/MRI centers, pathology labs, collection centres, and tele-reporting hubs over the last one year.
Recent wins of radiology tenders in Maharashtra and Madhya Pradesh, besides contracts for Bhabha Atomic Research Centre, firmly set the pipeline of radiology projects for Krsnaa in FY25, signalling further growth in the diagnostics segment.
Do you have a news tip for Lakshmishree reporters? Please email us at media@lakshmishree.com
Source: Moneycontrol
News Desk
